Corona Remedies Limited confirmed that its officials will attend an analyst and investor meeting organized by Phillip Capital PCG. The session is scheduled for Wednesday, August 26, 2026, at 11:00 am in Ahmedabad.

The company stated that discussions during the group meeting will be restricted to publicly available information. No unpublished price sensitive information (UPSI) will be shared, adhering to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Event Details

Chetna Dharajiya, Company Secretary and Compliance Officer, issued the intimation on August 20, 2026. The company noted that schedule changes may occur due to exigencies from the host or the company. This disclosure is also available on the company’s website.

Corona Remedies officials will attend two major investor conferences in Mumbai this week, engaging with analysts and institutional investors through group and one-on-one meetings. The participation aims to provide market participants with updates on the company’s performance and outlook, utilizing only publicly available information to ensure regulatory compliance and transparency.

The engagements are scheduled for August 13 and 14, 2026, aligning with the timelines of the Emkay Global Investor Conference and the Equirus Investor Conference respectively. These interactions are critical for maintaining open communication channels with the investment community, allowing stakeholders to clarify queries regarding the company’s strategic direction and operational metrics without disclosing any unpublished price-sensitive information (UPSI).

Conference Schedule

The company has detailed the specific timing and nature of these engagements in its intimation to the stock exchanges. The schedule is as follows:

Regulatory Compliance

The intimation was issued pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates that listed entities disclose their participation in analyst or investor conferences to ensure equitable dissemination of information to all stakeholders.

Chetna Dharajiya, Company Secretary and Compliance Officer of Corona Remedies Limited, signed the disclosure on August 10, 2026. The notice explicitly states that no UPSI will be discussed during these sessions, reinforcing the company’s adherence to insider trading norms and fair disclosure practices.

Market Implications

While no new financial data will be released during these meetings, such conferences often serve as a barometer for investor sentiment. Analysts from Emkay Global and Equirus will likely focus on the company’s recent quarterly performance, pipeline developments, and broader industry trends affecting the pharmaceutical sector. The in-person format allows for more nuanced discussions compared to virtual interactions, potentially leading to deeper insights into management’s strategic priorities.

Investors are advised to monitor the company’s website at www.coronaremedies.com for any subsequent updates or changes to the schedule due to exigencies on the part of the host or the company. The disclosures were simultaneously filed with the Listing Operation Department of BSE Limited and the Listing Compliance Department of National Stock Exchange of India Limited.